Top
Summary
All studies
Serious outcomes
Recovery
RCTs
Peer-reviewed
All outcomes

Feedback
Analgesics⏵
Antiandrogens⏵
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
Top
All glenzocimab studies
 
Feedback
Home
c19early.org COVID-19 treatment researchGlenzocimabGlenzocimab (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 glenzocimab studies

Home
Post
Share
@CovidAnalysis
StudiesStudies
FeedbackFeedback
All studies   Serious outcomes   Recovery   RCTs   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -60% 1 62 Improvement, Studies, Patients Relative Risk RCTs -60% 1 62 Early -60% 1 62 Glenzocimab for COVID-19 c19early.org June 2024 Favorsglenzocimab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pottecher (DB RCT) -60% 1.60 [0.76-3.36] progression 12/30 8/32 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Early treatment -60% 1.60 [0.76-3.36] 12/30 8/32 60% higher risk All studies -60% 1.60 [0.76-3.36] 12/30 8/32 60% higher risk 1 glenzocimab COVID-19 study c19early.org June 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Effect extraction pre-specified(most serious outcome) Favors glenzocimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pottecher (DB RCT) -60% 1.60 [0.76-3.36] progression 12/30 8/32 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Early treatment -60% 1.60 [0.76-3.36] 12/30 8/32 60% higher risk All studies -60% 1.60 [0.76-3.36] 12/30 8/32 60% higher risk 1 glenzocimab COVID-19 serious outcome c19early.org June 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Effect extraction pre-specified(most serious outcome) Favors glenzocimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pottecher (DB RCT) -49% 1.49 [0.53-4.20] no recov. 7/30 5/32 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.46 Early treatment -49% 1.49 [0.53-4.20] 7/30 5/32 49% higher risk All studies -49% 1.49 [0.53-4.20] 7/30 5/32 49% higher risk 1 glenzocimab COVID-19 recovery result c19early.org June 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.46 Favors glenzocimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pottecher (DB RCT) -60% 1.60 [0.76-3.36] progression 12/30 8/32 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Early treatment -60% 1.60 [0.76-3.36] 12/30 8/32 60% higher risk All studies -60% 1.60 [0.76-3.36] 12/30 8/32 60% higher risk 1 glenzocimab COVID-19 Randomized Controlled Trials c19early.org June 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Effect extraction pre-specified(most serious outcome) Favors glenzocimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pottecher (DB RCT) -60% 1.60 [0.76-3.36] progression 12/30 8/32 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Early treatment -60% 1.60 [0.76-3.36] 12/30 8/32 60% higher risk All studies -60% 1.60 [0.76-3.36] 12/30 8/32 60% higher risk 1 glenzocimab COVID-19 peer reviewed studies c19early.org June 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Effect extraction pre-specified(most serious outcome) Favors glenzocimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pottecher (DB RCT) -60% 1.60 [0.76-3.36] progression 12/30 8/32 Improvement, RR [CI] Treatment Control Pottecher (DB RCT) -54% 1.54 [0.77-3.07] progression 13/30 9/32 Pottecher (DB RCT) -49% 1.49 [0.53-4.20] no recov. 7/30 5/32 Pottecher (DB RCT) -413% 5.13 [0.26-103] no recov. 2/30 0/32 Glenzocimab COVID-19 outcomes c19early.org June 2024 Favors glenzocimab Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0